1. Home
  2. NXJ vs KROS Comparison

NXJ vs KROS Comparison

Compare NXJ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New Jersey Qualified Municipal Fund

NXJ

Nuveen New Jersey Qualified Municipal Fund

HOLD

Current Price

$12.47

Market Cap

503.5M

Sector

Finance

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$13.66

Market Cap

584.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXJ
KROS
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
584.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NXJ
KROS
Price
$12.47
$13.66
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$23.00
AVG Volume (30 Days)
112.1K
277.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.27%
N/A
EPS Growth
N/A
3.85
EPS
N/A
2.68
Revenue
N/A
N/A
Revenue This Year
N/A
$6,898.87
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.01
Revenue Growth
N/A
N/A
52 Week Low
$11.01
$9.12
52 Week High
$12.90
$22.55

Technical Indicators

Market Signals
Indicator
NXJ
KROS
Relative Strength Index (RSI) 40.50 23.64
Support Level $11.24 $13.42
Resistance Level $12.76 $15.02
Average True Range (ATR) 0.09 0.60
MACD -0.01 -0.22
Stochastic Oscillator 17.21 15.85

Price Performance

Historical Comparison
NXJ
KROS

About NXJ Nuveen New Jersey Qualified Municipal Fund

Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: